anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The most common adverse reaction observed in controlled clinical trials with TRAVATAN and TRAVATAN Z was ocular hyperemia, which was reported in 30% to 50% of patients. Up to 3% of patients discontinued therapy due to conjunctival hyperemia. Ocular adverse reactions, reported at an incidence of 5% to 10% in these clinical trials, included decreased visual acuity, eye discomfort, foreign body sensation, pain, and pruritus.

Ocular adverse reactions, reported at an incidence of 1% to 4% in clinical trials with TRAVATAN or TRAVATAN Z, included abnormal vision, blepharitis, blurred vision, cataract, conjunctivitis, corneal staining, dry eye, iris discoloration, keratitis, lid margin crusting, ocular inflammation, photophobia, subconjunctival hemorrhage, and tearing.

Non-ocular adverse reactions, reported at an incidence of 1% to 5% in these clinical studies, were allergy, angina pectoris, anxiety, arthritis, back pain, bradycardia, bronchitis, chest pain, cold/flu syndrome, depression, dyspepsia, gastrointestinal disorder, headache, hypercholesterolemia, hypertension, hypotension, infection, pain, prostate disorder, sinusitis, urinary incontinence, and urinary tract infections.
FIELD: chemistry. ^ SUBSTANCE: invention relates to novel substituted tetracyclic derivatives of tetrahydropyran, pyrrolidine and tetrahydrothiophene of general formula (I), their pharmaceutically acceptable addition salts, their stereochemically isomeric forms, their N-oxide forms, in which all substitutes are defined in claim 1 of the formula of invention. These compounds have binding affinity to serotonin receptors, particularly 5-HT2A and 5-HT2C receptors, and to dopamine receptors particularly D2 dopamine receptors, and have norepiniphrine reuptake inhibition properties. The invention also relates to a pharmaceutical composition containing said compounds, method of preparing said composition and use of said compounds as medicinal agents, particularly for preventing and/or treating several psychiatric and neurological disorders. ^ EFFECT: new compounds have useful biological properties. ^ 12 cl, 3 tbl, 49 ex
This intervention will be given once a day, 30 minutes before feeding schedule based on the neonatologist. Each session of intervention will take time about 18 minutes.
Hematologic: Pioglitazone may cause decreases in hemoglobin and hematocrit. The fall in hemoglobin and hematocrit with pioglitazone appears to be dose related. Across all clinical studies, mean hemoglobin values declined by 2% to 4% in patients treated with pioglitazone. These changes generally occurred within the first 4 to 12 weeks of therapy and remained relatively stable thereafter. These changes may be related to increased plasma volume associated with pioglitazone therapy and have rarely been associated with any significant hematologic clinical effects (see PRECAUTIONS, General: Pioglitazone hydrochloride). 

In controlled clinical trials of metformin at 29 weeks' duration, a decrease to subnormal levels of previously normal serum vitamin B12 levels, without clinical manifestations, was observed in approximately 7% of patients. Such decrease, possibly due to interference with B12 absorption from the B12 -intrinsic factor complex, is, however, very rarely associated with anemia and appears to be rapidly reversible with discontinuation of metformin or vitamin B12 supplementation (see PRECAUTIONS, General: Metformin hydrochloride).

Serum Transaminase Levels: During all clinical studies in the U.S., 14 of 4780 (0.30%) patients treated with pioglitazone had ALT values ≥ 3 times the upper limit of normal during treatment. All patients with follow-up values had reversible elevations in ALT. In the population of patients treated with pioglitazone, mean values for bilirubin, AST, ALT, alkaline phosphatase, and GGT were decreased at the final visit compared with baseline. Fewer than 0.9% of patients treated with pioglitazone were withdrawn from clinical trials in the U.S. due to abnormal liver function tests.

In pre-approval clinical trials, there were no cases of idiosyncratic drug reactions leading to hepatic failure (see PRECAUTIONS, General: Pioglitazone hydrochloride).

CPK Levels: During required laboratory testing in clinical trials with pioglitazone, sporadic, transient elevations in creatine phosphokinase levels (CPK) were observed. An isolated elevation to greater than 10 times the upper limit of normal was noted in 9 patients (values of 2150 to 11400 IU/L). Six of these patients continued to receive pioglitazone, two patients had completed receiving study medication at the time of the elevated value and one patient discontinued study medication due to the elevation. These elevations resolved without any apparent clinical sequelae. The relationship of these events to pioglitazone therapy is unknown.
FIELD: veterinary medicine. SUBSTANCE: method involves adding Permait and cryogenic pumpkin powder (Cucubita pepo L.) to animal food according to a scheme. Permait is given to cows beginning from 5-6 month of pregnancy at a dose of 250 g per animal daily during 60 days. Cryogenic pumpkin powder is given at a dose of 50 g per cow during 20 days. Swine are treated beginning from the first-second month after gestation with 150 g of Permait and 20 g of pumpkin powder per animal daily during 30 days. EFFECT: high survival percentage of newborn pigs. 2 tbl
MOTIVATION: Despite the widespread occurrence of polyploids across the Tree of Life, especially in the plant kingdom, very few computational methods have been developed to handle the specific complexities introduced by polyploids in phylogeny estimation. Furthermore, methods that are designed to account for polyploidy often disregard incomplete lineage sorting (ILS), a major source of heterogeneous gene histories, or are computationally very demanding. Therefore, there is a great need for efficient and robust methods to accurately reconstruct polyploid phylogenies.
RESULTS: We introduce Polyphest (POLYploid PHylogeny ESTimation), a new method for efficiently and accurately inferring species phylogenies in the presence of both polyploidy and ILS. Polyphest bypasses the need for extensive network space searches by first generating a multilabeled tree based on gene trees, which is then converted into a (uniquely labeled) species phylogeny. We compare the performance of Polyphest to that of two polyploid phylogeny estimation methods, one of which does not account for ILS, namely PADRE, and another that accounts for ILS, namely MPAllopp. Polyphest is more accurate than PADRE and achieves comparable accuracy to MPAllopp, while being significantly faster. We also demonstrate the application of Polyphest to empirical data from the hexaploid bread wheat and confirm the allopolyploid origin of bread wheat along with the closest relatives for each of its subgenomes.
AVAILABILITY AND IMPLEMENTATION: Polyphest is available at https://github.com/NakhlehLab/Polyphest.
Forced-air warming device (3M device). In this arm, the 3M blanket will be conected to forced-air machine and warmed to 41 degrees before patients lay down.
This is the control group. Consented providers will perform catherization procedures utilizing only the lead apron and ancillary shields (lead skirt, vest, thyroid collar (all at least 0.5mm Pb) with use of under table lead per lab operating policy and mobile suspended lead-acrylic shield and lead glasses). Radiation will be measured by dosimeters worn by the providers.
The purpose of this study is to investigate the relationship between chronic pain and the mortality rate of cerebrovascular disease (CVD) in cancer patients. Thus, we performed a case-control investigation was conducted by utilizing data from the Surveillance, Epidemiology, and End Results (SEER) database between 1975 and 2019. Multiple demographics, pain rating and other clinical characteristics were extracted to assess predictors for the death from CVD in cancer patients. Different machine learning algorithms were applied to construct pain-related prediction model. The analysis involved 16,850 case patients and 710,729 controls. Among cancer patients, approximately 2.3% succumbed to subsequent CVD. Cancer pain (Pain rating II) was associated with a decreased risk of CVD. Univariate and multivariate COX analyses indicated that older age at cancer diagnosis, male gender, single marital status, Black or Other race, and lack of systemic therapy correlated with a higher risk of CVD-related death. Propensity score matching revealed a significantly lower proportion of Pain rating II in the case group. The logistic regression algorithm demonstrated superior predictive ability for 5-year and 10-year CVD risk in cancer patients. Notably, survival time, age, and pain rating emerged as the top three crucial variables. This study firstly investigated pain and various risk factors for CVD in cancer patients, highlighting pain as a novel and possible protective factor for CVD. The development of a risk model based on pain could aid in identifying individuals at high risk for CVD and may inspire innovative strategies for preventing CVD in cancer patients.
PURPOSE: A composition containing Cinnamomum cassia extract, fraction thereof, trans-cinnamaldehyde isolated from the same is provided to protect dopamine neural cell damage. CONSTITUTION: A composition for preventing and treating Parkinson's disease contains Cinnamomum cassia extract as an active ingredient. The extract is obtained from branch or bark of Cinnamomum cassia using water, low alcohol of C1-C4, or mixture solvent. A composition for preventing and treating Parkinson's disease contains Cinnamomum cassia organic solvent fraction which is obtained by using organic solvent. The organic solvent is ethylacetate or butanol. A composition for preventing and treating Parkison's disease contains trans-cinnamaldehyde or pharmaceutically acceptable salt as an active ingredient.
RATIONALE AND OBJECTIVES: This study aimed to investigate the structural and functional alterations occurring within bilateral premotor thalamus (mPMtha) in motor subtypes of Parkinson's disease (PD).
MATERIALS AND METHODS: Sixty-one individuals with instability and gait difficulty (PIGD) subtype, 60 individuals with tremor-dominant (TD) subtype and 66 healthy controls (HCs) participated in the study. All participants underwent resting-state functional magnetic resonance imaging (rs-fMRI) and 3D T1-weighted (3DT1) scans. Functional connectivity (FC) analysis and Voxel-based morphometry (VBM) analysis were performed to evaluate the function and volume of mPMtha. Additionally, correlations between motor performance and FC values, volumes were examined separately. Support vector machine (SVM) model based on FC values and thalamic volumes was conducted to assist in the clinical diagnosis of PD motor subtype.
RESULTS: Compared to HCs and PIGD, TD subtype showed increased FC between the bilateral mPMtha and left middle occipital gyrus, left inferior parietal lobule (IPL). While PIGD subtype demonstrated decreased FC between right mPMtha and precentral gyrus (PreCG), supramarginal, IPL and superior parietal lobule. FC of bilateral mPMtha with the identified regions were significantly correlated with motor performance scores in PD patients. The SVM classification based on FC values demonstrated a high level of efficiency (AUC=0.874). The volumes of the bilateral mPMtha were indifferent among three groups.
CONCLUSION: We noted distinct FC alterations of mPMtha in TD and PIGD subtypes, and these changes were correlated with motor performance. Furthermore, the machine learning based on statistically significant FC might be served as an alternative approach for automatically classifying PD motor subtypes individually.
OBJECTIVE: To assess the impact of vagus nerve stimulation (VNS) on quality of life contributors such as rescue medications.
METHODS: Using the seizure diary application SeizureTracker™ database, we examined trends in rescue administration frequency before and after the first recorded VNS magnet swipe in patients with drug-resistant epilepsy who had 1) At least one VNS magnet swipe recorded in the diary, and 2) Recorded usage of a benzodiazepine rescue medication (RM) within 90 days prior to the first swipe. A paired Wilcoxon rank-sum test was used to assess changes in RM usage frequency between 30-, 60-, 90-, 180- and 360-day intervals beginning 30 days after first magnet swipe. Longitudinal changes in RM usage frequency were assessed with a generalized estimating equation model.
RESULTS: We analyzed data of 95 patients who met the inclusion criteria. Median baseline seizure frequency was 8.3 seizures per month, with median baseline rescue medication usage frequency of 2.1 administrations per month (SD 3.3). Significant reductions in rescue medication usage were observed in the 91 to 180 day interval after first VNS magnet swipe, and at 181 to 360 days and at 361 to 720 days, with the magnitude of reduction increasing over time. Decreases in rescue medication usage were sustained when controlling for patients who did not record rescue medication use after the first VNS magnet swipe (N=91). Significant predictors of reductions in rescue medication included baseline frequency of rescue medication usage and time after first VNS magnet swipe.
SIGNIFICANCE: This retrospective analysis suggests that usage of rescue medications is reduced following the start of VNS treatment in patients with epilepsy, and that the magnitude of reduction may progressively increase over time.
An overall pharmacy system and methodology begins with bulk medications and supplements introduced into the work flow, individually packaged and assembled into med pass orders per patient and delivered to the long-term care (LTC) facility or other institution for patient consumption. The process according to one embodiment of this invention begins by converting bulk medications and supplements to packaged unit doses and ultimately individually packaged med pass bags for each patient on a 24-hour schedule. The various safeguards and measures built into this system increase patient safety eliminate waste and increase labor efficiency by reducing and/or minimizing the disposal of unused medications and supplements. The design of the overall system and its individual components allows for physical control of each unit dose package from start to finish without any unit dose package “free fall” in the system. This process is automated and does not rely upon manual sorting. The med pass bags are consolidated into the final shipping container and do not require manual sorting and packing.
Cognitive impairment is common in extracerebral diseases such as chronic kidney disease (CKD). Kidney transplantation reverses cognitive impairment, indicating that cognitive impairment driven by CKD is therapeutically amendable. However, we lack mechanistic insights allowing development of targeted therapies. Using a combination of mouse models (including mice with neuron-specific IL-1R1 deficiency), single cell analyses (single-nuclei RNA-sequencing and single-cell thallium autometallography), human samples and in vitro experiments we demonstrate that microglia activation impairs neuronal potassium homeostasis and cognition in CKD. CKD disrupts the barrier of brain endothelial cells in vitro and the blood-brain barrier in vivo, establishing that the uremic state modifies vascular permeability in the brain. Exposure to uremic conditions impairs calcium homeostasis in microglia, enhances microglial potassium efflux via the calcium-dependent channel KCa3.1, and induces p38-MAPK associated IL-1β maturation in microglia. Restoring potassium homeostasis in microglia using a KCa3.1-specific inhibitor (TRAM34) improves CKD-triggered cognitive impairment. Likewise, inhibition of the IL-1β receptor 1 (IL-1R1) using anakinra or genetically abolishing neuronal IL-1R1 expression in neurons prevent CKD-mediated reduced neuronal potassium turnover and CKD-induced impaired cognition. Accordingly, in CKD mice, impaired cognition can be ameliorated by either preventing microglia activation or inhibiting IL-1R-signaling in neurons. Thus, our data suggest that potassium efflux from microglia triggers their activation, which promotes microglia IL-1β release and IL-1R1-mediated neuronal dysfunction in CKD. Hence, our study provides new mechanistic insight into cognitive impairment in association with CKD and identifies possible new therapeutic approaches.
<P>PROBLEM TO BE SOLVED: To support self-dosage management by a patient or a caregiver of the patient so as to prevent twice drinking or drinking failure.  <P>SOLUTION: An electronic lock is mounted to a medicine vessel. The electronic lock comprises an electronic lock drive circuit 23 and a locking mechanism 24. An electronic control device including a CPU 11 and a RAM 13, on detecting a start timing of a dosage period, releases the electronic lock. The electronic control device, on detecting a closing signal from a medicine vessel sensor 15 and a closing signal from a medicine shell vessel sensor 16, stores the present time as a dosage recognizing time in the RAM 13, displays the dosage recognizing time T on a liquid crystal display 20, and then locks the electronic lock. Thus, the medicine vessel is kept in an open/close impossible state from the dosage recognizing time to a start time of the next dosage period. When the electronic lock lies in the locking state, operation of a recognizing switch 18 re-displays the dosage recognizing time T on the liquid crystal display 20.  <P>COPYRIGHT: (C)2003,JPO
FIELD: medicine.SUBSTANCE: invention relates to medicine, particularly, to neurology, and can be used to identify brain activation areas linking interoception and emotional intelligence. Functional magnetic resonance imaging (fMRI) of the brain is performed in the T2* mode with a block design. Scanning is therein executed in the process of performing sixteen blocks alternating eight interoceptive blocks - "heartbeat" and eight exteroceptive blocks - "sounds". During each “heartbeat” block therein, the subject focuses the attention on the heart and listens to his/her own heartbeat for the duration of 10 scans. During each “sounds” block, a “beep” signal is sent to the headphones at a frequency equivalent to the heart rate of the subject, and the subject focuses on the sounds for the duration of 10 scans. The obtained 160 scans are then processed in the T2* mode with selection of activation areas corresponding with the "heartbeat" interoceptive block, by calculating the difference in activation between the "heartbeat" interoceptive block and the "sounds" exteroceptive block. The brain activation areas connecting interoception and emotional intelligence are then identified by means of superimposing the maps obtained in the T2* mode with the obtained activation difference on the volumetric reconstruction of the brain obtained in the 3D-T1 mode.EFFECT: method ensures expansion of the range of technical means for identifying the brain activation areas linking interoception and emotional intelligence, particularly, in extending the available diagnostic capabilities to the category of middle-aged and elderly patients.1 cl, 2 dwg, 3 ex
FIELD: biotechnology. SUBSTANCE: protein (usually enzyme, preferably hydrolase) in soluble form is converted into form of cross-linked crystal by action with multifunctional cross-linking agent. Cross-linked crystal can be used as base for devices predominantly designed to be applied as biosensors. Cross- linked crystals can also be used in biotechnological synthesis to immobilize enzyme needed for a reaction. EFFECT: prolonged life time of proteins. 40 cl, 12 dwg, 19 tbl, 7 ex
Background and Objectives: Dementia is increasing worldwide. This study aimed to examine the impact of comorbidity burden and frailty on dementia prognosis in patients with dementia. Materials and Methods: This retrospective cohort study was conducted with 47 patients with dementia who were followed for up to two years. The Modified Charlson Comorbidity Index (MCCI), Mini-Mental State Examination (MMSE-E), and Edmonton Fragility Scale were used besides laboratory and clinical findings. Results: The mean age of the 47 patients was 78.77 ± 12.44 years. During the follow-up period, MMSE-E scores were observed to improve in 50% of the patients. Initial MMSE-E scores were found to be lowest in men and patients with coronary artery disease or depression, while final MMSE-E scores were observed to be lowest in patients with depression and low vitamin B12 or vitamin D levels. The rates of decrease in MMSE-E scores in non-, moderately and severely frail patients were 21.4%, 55.6%, and 70.6%, respectively. There was a moderate negative correlation between MMSE-E scores and both comorbidity burden and frailty scores. The mediation analysis revealed that frailty was a complete mediator, and that comorbidity burden led to an increase in frailty and a decrease in MMSE-E scores. During the follow-up period, patients with moderate frailty, hypertension, diabetes mellitus, alcohol and tobacco use, low B12 levels, or hypothyroidism showed an increased risk of decrease in cognitive functions. Conclusions: There was a significant association between dementia prognosis and both frailty and biological deficits. We recommend the adoption of a syndemic approach in the follow-up of dementia, as we believe that the prevention of frailty and associated biological deficits will contribute to slowing dementia's clinical course.
1,127,457. Acyl N-methylpiperazines. FARBWERKE HOECHST A.G. 24 Jan., 1966 [27 Jan., 1965], No. 3105/66. Heading C2C. Compounds of the formula wherein R represents a branched or unbranched alkyl group containing 3 carbon atoms or a cyclic group containing 5 to 7 ring carbon atoms, physiologically tolerable acid addition salts thereof and preparation thereof by treating N-methyl-piperazine with a reactive derivative of a carboxylic acid of the formula R.COOH (for example a halide, a simple or mixed anhydride, an azide or an imidazolide) in an organic solvent in the presence of an acid binding agent. The compounds of the first general formula above may also be prepared by reacting a compound of the formula with a methylating agent such as a methyl ester of a strong inorganic acid in neutral or alkaline solution or by selective catalytic hydrogenation of a compound of the formula wherein R 1  represents an unsaturated group which is capable of conversion into the group R as defined above by hydrogenation using platinum, palladium or nickel catalysts in a suitable solvent. The preparation of butyric acid N-methyl-piperazide is described and a number of other N-methyl-piperazides are identified. Pharmaceutical compositions suitable for oral or parenteral administration in the treatment of anthelminthiasis, particularly filiariasis, e.g. due to Litosomoides carinii, comprise a compound of the first general formula above or a physiologically tolerable acid addition salt thereof optionally in association with specified pharmaceutically suitable carriers.
Al18F-octreotide PET/CT will be performed on patients with suspected or clearly diagnosed Neuroendocrine Tumor. The patients were injected with Al18F-octreotide and underwent PET/CT scan 20\~40min after the injection.